{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:01:02Z","timestamp":1780416062861,"version":"3.54.1"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Statin use has been associated with improved survival in patients with breast cancer, but there are no data on the association between statin use and survival in different intrinsic breast cancer subtypes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the associations between statin use and survival in patients with early breast cancer of different intrinsic subtypes.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective population-based cohort study of female patients with invasive breast cancer diagnosed in Finland between 1995 and 2013. The cohort was limited to early breast cancer cases with sufficient data for surrogate intrinsic subtyping. All data originated from Finnish national registries. Statistical analyses were performed from September to November 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Statin use, statin dose, and blood cholesterol levels before and after diagnosis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n All-cause and breast cancer\u2013specific mortality during follow-up.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 7389 female patients with early breast cancer were included (median [range] age at diagnosis, 60 [21-102] years). Prediagnostic statin use was not associated with breast cancer\u2013specific or all-cause mortality. Postdiagnostic statin use was associated with lower age-adjusted breast cancer\u2013specific (hazard ratio [HR], 0.68; 95% CI, 0.57-0.82) and all-cause (HR, 0.83; 95% CI, 0.75-0.92) mortality. In a multivariable-adjusted model, statin use was associated with higher breast cancer\u2013specific survival in all hormone receptor\u2013positive subtypes (luminal A-like, luminal B-like [HER2-negative], and luminal B-like [HER2-positive]). All-cause mortality was lower among statin users in patients with hormone positive and triple-negative subtypes. One-year lag-time analysis or adjustment for blood-cholesterol levels after breast cancer diagnosis did not affect the results substantially. While the benefit of statin use was noticed in all statin users regardless of dose intensity, a trend of dose-dependent risk reduction was observed regarding breast cancer\u2013specific mortality.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with early breast cancer, prediagnostic statin use was not associated with higher survival; however, postdiagnostic statin use was associated with lower all-cause and breast cancer\u2013specific mortality among patients with hormone receptor\u2013positive intrinsic subtypes. These findings suggest that statin therapy may improve survival of patients with early hormone receptor\u2013positive subtypes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.16375","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:00:27Z","timestamp":1780412427000},"page":"e2616375","source":"Crossref","is-referenced-by-count":0,"title":["Statin Use and Survival in Early Breast Cancer According to Different Intrinsic Subtypes"],"prefix":"10.1001","volume":"9","author":[{"given":"Santeri","family":"Palmi","sequence":"first","affiliation":[{"name":"Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere, Finland"},{"name":"Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otso","family":"Arponen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere, Finland"},{"name":"Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland"},{"name":"Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Murto","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland"},{"name":"Department of General Surgery, Waikato Hospital, Hamilton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"Siltari","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland"},{"name":"Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"Jukkola","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere, Finland"},{"name":"Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teemu","family":"Murtola","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland"},{"name":"Department of Urology, Tays Cancer Center, Tampere University Hospital, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"8","key":"zoi260461r3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"zoi260461r4","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer.","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"issue":"2","key":"zoi260461r5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijc.31914","article-title":"Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study.","volume":"144","author":"van Maaren","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"zoi260461r6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12885-016-2766-3","article-title":"Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study.","volume":"16","author":"Hennigs","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"zoi260461r7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes.","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"zoi260461r8","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1200\/JCO.22.02511","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes.","volume":"41","author":"Parker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260461r9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi260461r10","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi260461r11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins.","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"4","key":"zoi260461r12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/187152012800228715","article-title":"Statins and protein prenylation in cancer cell biology and therapy.","volume":"12","author":"Garc\u00eda-Ruiz","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"zoi260461r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-024-07605-2","article-title":"The role of statins in breast cancer survivors.","volume":"210","author":"Bashey","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"zoi260461r14","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s12276-023-01079-w","article-title":"Functional significance of cholesterol metabolism in cancer: from threat to treatment.","volume":"55","author":"Xiao","year":"2023","journal-title":"Exp Mol Med"},{"key":"zoi260461r15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241908","article-title":"Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.","author":"Nelson","year":"2013","journal-title":"Science (1979)"},{"issue":"1","key":"zoi260461r16","first-page":"10","article-title":"The statins as anticancer agents.","volume":"9","author":"Chan","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"zoi260461r17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/jcm9020326","article-title":"Statin and cancer mortality and survival: An umbrella systematic review and meta-analysis.","volume":"9","author":"Jeong","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"zoi260461r18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12885-016-2651-0","article-title":"Statin use and breast cancer survival: a nationwide cohort study in Scotland.","volume":"16","author":"Mc Menamin","year":"2016","journal-title":"BMC Cancer"},{"issue":"5","key":"zoi260461r19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/bjc.2016.232","article-title":"De novo post-diagnosis statin use, breast cancer\u2013specific and overall mortality in women with stage I-III breast cancer.","volume":"115","author":"Smith","year":"2016","journal-title":"Br J Cancer"},{"issue":"5","key":"zoi260461r20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00404-021-06065-z","article-title":"The relationship between post-diagnostic statin usage and breast cancer prognosis varies by hormone receptor phenotype: a systemic review and meta-analysis.","volume":"304","author":"Xu","year":"2021","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"zoi260461r21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12885-018-5263-z","article-title":"Statin use and breast cancer survival - a Swedish nationwide study.","volume":"19","author":"Borgquist","year":"2019","journal-title":"BMC Cancer"},{"key":"zoi260461r22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256747","article-title":"Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis.","volume":"13","author":"Jia","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"zoi260461r23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41416-025-03070-w","article-title":"Statin use and breast cancer\u2013specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics.","volume":"133","author":"Scott","year":"2025","journal-title":"Br J Cancer"},{"key":"zoi260461r24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.835320","article-title":"The impact of statin use and breast cancer recurrence\u2014a retrospective study in Singapore.","volume":"12","author":"Sim","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"zoi260461r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.43861","article-title":"Statin use, cholesterol level, and mortality among females with breast cancer.","volume":"6","author":"Murto","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi260461r26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110231","article-title":"Statin use and breast cancer survival: a nationwide cohort study from Finland.","volume":"9","author":"Murtola","year":"2014","journal-title":"PLoS One"},{"key":"zoi260461r27","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1425193","article-title":"Nordic Cancer Registries\u2013an overview of their procedures and data comparability.","author":"Pukkala","year":"2018","journal-title":"Acta Oncol (Madr)"},{"issue":"6","key":"zoi260461r29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"zoi260461r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104507","article-title":"The association between intrinsic breast cancer subtypes, mammography screening and prognosis: a large population-based real world cohort study.","volume":"82","author":"Palmi","year":"2025","journal-title":"Breast"},{"issue":"8","key":"zoi260461r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167458","article-title":"Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high\/HER2-positive breast cancer.","volume":"1870","author":"Kato","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"10","key":"zoi260461r34","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/S1470-2045(14)70119-6","article-title":"Statins and breast cancer prognosis: evidence and opportunities.","volume":"15","author":"Ahern","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi260461r35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-020-05749-5","article-title":"Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.","volume":"183","author":"Harborg","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"zoi260461r1","volume-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"zoi260461r2","unstructured":"Pitk\u00e4niemi? J, Malila? N, Heikkinen? S, Sepp\u00e4? K. Tilastoraportti Suomen Sy\u00f6p\u00e4tilanteesta. SY\u00d6P\u00c4. 2022. Accessed April 23, 2026. https:\/\/syoparekisteri.fi\/assets\/themes\/ssy3\/factsheets\/syopa_2022_tilastoraportti.html"},{"key":"zoi260461r28","unstructured":"Finnish Cancer Registry. 2025. Accessed September 24, 2025. https:\/\/cancerregistry.fi\/statistics\/"},{"key":"zoi260461r31","unstructured":"Martikainen? J, Rajaniemi? S. Drug reimbursement. 2002. Accessed April 23, 2026. https:\/\/helda.helsinki.fi\/bitstreams\/4ed6565b-398c-4c38-8ea3-39350fa7266d\/download"},{"key":"zoi260461r32","unstructured":"World Health Organization Collaborating Centre for Drug StatisticsMethodology. ATC\/DDD Index 2021. Accessed June 28, 2023. https:\/\/atcddd.fhi.no\/atc_ddd_index\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849782\/palmi_2026_oi_260461_1779815520.90546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:00:31Z","timestamp":1780412431000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.16375","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}